AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Report Publication Announcement Feb 13, 2025

7612_rns_2025-02-13_6516c426-ef96-408c-b627-5a4528534f2d.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 9272W

Eco Animal Health Group PLC

13 February 2025

13 February 2025

ECO Animal Health Group plc

("ECO" or the "Company")

Notice of R&D Day

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it will be holding an in-person and virtual R&D Day for investors and analysts on 13 March 2025, from 14:00 GMT at Andaz London, 40 Liverpool St, London EC2M 7QN.

The event will be led by David Hallas, CEO, and Chris Wilks, CFO, alongside senior leaders from across the Company and an industry expert. Attendees will have the opportunity to gain valuable insights on how the next generation of assets in ECO's R&D pipeline are driving long-term value creation and future proofing the business through innovations in preventative animal health.

To confirm your interest in the R&D Day please contact [email protected].

-Ends-

For further information please contact:

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)
020 8447 8899
Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher
020 7496 3000
Investec (Joint Broker)

Gary Clarence

Lydia Zychowska
020 7597 5970
Equity Development

Hannah Crowe

Matt Evans
020 7065 2692
ICR Healthcare (Financial PR)

Mary-Jane Elliott

Jessica Hodgson
020 3709 5700

[email protected]

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKZGMZGZKGKZZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.